CABIMER-Andalusian Center for Molecular Biology and Regenerative Medicine (CSIC-University of Seville-UPO-Junta de Andalucia), Seville, Spain.
Nanomedicine. 2010 Aug;6(4):523-9. doi: 10.1016/j.nano.2010.01.001. Epub 2010 Jan 18.
Dendritic cells (DCs) are potent antigen-presenting cells capable of initiating a primary immune response and possess the ability to activate T cells and stimulate the growth and differentiation of B cells. DCs provide a direct connection between innate and adaptive immune response, and arise from bone marrow precursors that are present in immature forms in peripheral tissues, where they are prepared to capture antigens. DCs migrate from the peripheral tissues to the closest lymph nodes through afferent lymphatic vessels to present the foreign antigens, stimulating T-cell activation and initiating a cellular immune response. Moreover, it is known that DCs have an important role in various diseases and conditions involving the immune system, particularly in cancer and autoimmune disorders. For these reasons, targeting nanoparticles (NPs) to DCs provides a promising strategy for developing an efficient balanced and protective immune response. NPs can modulate the immune response and might be potentially useful as effective vaccine adjuvants for infectious disease and cancer therapy. The objective of this review is to present the latest advances in NP delivery methods targeting DCs, the mechanisms of action, potential effects, and therapeutic results of these systems and their future applications, such as improved vaccination strategies, cancer immunotherapy, and immunomodulatory treatments. From the clinical editor: Dendritic cells (DCs) are potent antigen-presenting cells capable of initiating a primary immune response and activating T and B cells. The role of DC-s can be considered as a bridge between innate and adaptive immunity. Targeting nanoparticles (NPs) to DCs can modulate the immune response and might be useful as vaccine adjuvants in infectious disease and cancer therapy.
树突状细胞 (DCs) 是一种强大的抗原呈递细胞，能够引发初始免疫反应，并具有激活 T 细胞和刺激 B 细胞生长和分化的能力。DCs 提供了先天免疫和适应性免疫反应之间的直接联系，起源于骨髓前体，这些前体以不成熟的形式存在于外周组织中，准备捕获抗原。DCs 通过输入淋巴管从外周组织迁移到最近的淋巴结，以呈现外来抗原，刺激 T 细胞激活并引发细胞免疫反应。此外，已知 DCs 在涉及免疫系统的各种疾病和病症中具有重要作用，特别是在癌症和自身免疫性疾病中。出于这些原因，将纳米颗粒 (NPs) 靶向 DCs 提供了一种有前途的策略，可用于开发有效的平衡和保护性免疫反应。NPs 可以调节免疫反应，并可能作为有效的疫苗佐剂用于传染病和癌症治疗。本综述的目的是介绍针对 DCs 的 NP 传递方法的最新进展、这些系统的作用机制、潜在影响和治疗结果及其未来应用，例如改进的疫苗接种策略、癌症免疫疗法和免疫调节治疗。从临床编辑的角度来看：树突状细胞 (DCs) 是一种强大的抗原呈递细胞，能够引发初始免疫反应并激活 T 细胞和 B 细胞。DCs 的作用可以被认为是先天免疫和适应性免疫之间的桥梁。将纳米颗粒 (NPs) 靶向 DCs 可以调节免疫反应，并可能作为传染病和癌症治疗中的疫苗佐剂有用。
